Rocket


Overview
Financials
News + Filings
Key Docs
Insiders

 
 

Sinorama Corp (TBD) Add to portfolio


Recent News + Filings   (All items)
Date FiledTypeDescription
06/28/2021 REVOKED Form REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]:
01/10/2019 GN Emerald Health Therapeutics Closes Emerald Health Naturals Joint Venture
12/10/2018 GN Emerald Health Sees License Expansion of Pure Sunfarms Cannabis Production Operation to 687,000 Square Feet, one of Largest Production Capacities in Canada
12/07/2018 GN Emerald Health Therapeutics Closes $10.8 Million Prospectus Sale
12/04/2018 GN Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System
11/30/2018 GN Emerald Health Therapeutics Reports 3rd Quarter 2018 Financial Results and Provides Corporate Update
11/28/2018 GN Emerald Health Therapeutics Announces Executive Chairman Avtar Dhillon Appointed as President; CEO Chris Wagner Steps Down


Financial Summary   (All financials)
In millions, except per share itemsDec-31-17Dec-31-16Dec-31-15Dec-31-14
Revenues98.377.70.036.0
            Revenue growth26.6%1075319.6%-100.0% 
Cost of goods sold85.371.92.62.2
Gross profit13.05.8-2.633.9
            Gross margin13.2%7.4%-35343.3%94.0%
Sales and marketing6.45.11.41.4
General and administrative0.81.00.20.3
EBIT-0.8-5.4-0.4-2.1
            EBIT margin-0.8%-7.0%-5563.2%-5.7%
Pre-tax income-0.6-5.6-0.3-2.0
Income taxes0.0-0.10.00.2
            Tax rate0.0%1.0%  
Net income-0.5-3.50.0-1.1
            Net margin-0.5%-4.4%469.5%-3.1%
 
Diluted EPS($0.03)($0.29)$0.00($0.22)
Shares outstanding (diluted)15.111.89.85.1
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy